New York State Teachers Retirement System Invests $3.06 Million in Indivior PLC $INDV

Key Points

• New York State Teachers Retirement System opened a new position in Indivior, buying 85,251 shares in Q4 valued at about $3.06 million (≈0.07% ownership); Vanguard and several other institutions also increased stakes, leaving institutional ownership at 60.33%.
• Analysts hold a consensus "Buy" on INDV with a $39.33 price target and multiple upgrades/price-target raises (e.g., HC Wainwright $48, Northland $50); the stock trades near $39.60, has a $4.83 billion market cap, reported $0.96 EPS on $317M revenue last quarter, and a one-year range of $10.63–$41.00.

New York State Teachers Retirement System acquired a new position in Indivior PLC (NASDAQ:INDV - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 85,251 shares of the company's stock, valued at approximately $3,059,000. New York State Teachers Retirement System owned about 0.07% of Indivior as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Jennison Associates LLC bought a new stake in shares of Indivior during the fourth quarter valued at approximately $685,000. State of New Jersey Common Pension Fund D raised its stake in shares of Indivior by 127.0% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 53,282 shares of the company's stock worth $1,912,000 after purchasing an additional 29,810 shares during the last quarter. Teachers Retirement System of The State of Kentucky purchased a new position in shares of Indivior in the fourth quarter worth $1,101,000. Vanguard Group Inc. raised its stake in shares of Indivior by 57.9% in the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company's stock worth $196,403,000 after purchasing an additional 2,008,078 shares during the last quarter. Finally, Salomon & Ludwin LLC purchased a new stake in Indivior during the fourth quarter valued at $30,000. 60.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on INDV shares. Zacks Research upgraded Indivior from a "hold" rating to a "strong-buy" rating in a research report on Monday, March 16th. HC Wainwright upped their price objective on Indivior from $35.00 to $48.00 and gave the stock a "buy" rating in a research note on Monday, January 12th. Northland Securities set a $50.00 price objective on Indivior in a research note on Tuesday, January 20th. Finally, Weiss Ratings lowered Indivior from a "hold (c+)" rating to a "hold (c)" rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $39.33.

Insider Buying and Selling at Indivior

In other Indivior news, Director Stuart A. Kingsley purchased 940 shares of Indivior stock in a transaction dated Friday, March 6th. The shares were purchased at an average cost of $31.86 per share, for a total transaction of $29,948.40. Following the completion of the acquisition, the director owned 5,582 shares in the company, valued at $177,842.52. This represents a 20.25% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.74% of the company's stock.

Indivior Price Performance

Shares of INDV stock opened at $39.60 on Friday. The stock's 50 day simple moving average is $32.24 and its two-hundred day simple moving average is $32.85. Indivior PLC has a 1 year low of $10.63 and a 1 year high of $41.00. The company has a market cap of $4.83 billion, a PE ratio of 20.31 and a beta of 0.90.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The firm had revenue of $317.00 million for the quarter. Equities research analysts expect that Indivior PLC will post 3.35 EPS for the current year.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.

Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.